Prostate Cancer · Men's Oncology

Investing at the
frontier of
men's oncology.

OneInEight Ventures backs the therapies, diagnostics, and platforms redefining outcomes for the 1 in 8 men diagnosed with prostate cancer.

Open Command Center Get in touch
1 in 8
Men diagnosed in their lifetime
3rd
Leading cause of cancer death in men
$5B+
Annual U.S. treatment market

Investment Thesis

A focused thesis in an underserved market.

Prostate cancer is one of oncology's largest markets — yet remains chronically underfunded relative to its clinical burden. We invest at the intersection of biology, technology, and unmet need.

Our strategy is built on pattern recognition across hundreds of therapeutics, diagnostics, and platform deals — identifying assets before consensus forms.

Novel Therapeutics

Targeted agents, radiopharmaceuticals, and next-generation hormone therapies addressing castration-resistant and metastatic disease.

Precision Diagnostics

Liquid biopsy, AI-driven imaging, and biomarker platforms enabling earlier detection and treatment stratification.

Platform Technologies

Drug delivery, target discovery, and combination-therapy platforms with broad applicability across the prostate cancer continuum.

Clinical Infrastructure

CRO models, trial optimization, and real-world evidence networks accelerating time-to-approval for validated assets.

Intelligence Platform

Track the market in real time.

The 1:8 Command Center aggregates deal flow, clinical updates, financings, and KOL intelligence — refreshed daily across 22 core companies.

Open Command Center Request access